The last decade has seen successful clinical application of polymer–protein conjugates (eg
Oncaspar, Neulasta) and promising results in clinical trials with polymer–anticancer drug …

Breast cancer, the most common form of cancer among women in North America and almost
all of Europe, is a significant health problem in terms of both morbidity and mortality. It is …

Purpose Recent data showed improvement in progression-free survival (PFS) when adding
everolimus to exemestane in patients with advanced breast cancer experiencing recurrence …

Over the last decade, polymer therapeutics have emerged as first-generation
nanomedicines.[1] The term polymer therapeutics was coined to include water-soluble …

Aldo-keto reductase (AKR) 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F
synthase) regulates ligand access to steroid hormone and prostaglandin receptors and may …

There is an urgent need to identify and develop a new generation of therapeutic agents and
systemic therapies targeting the estradiol (E2)/estrogen receptor (ER) signaling in breast …

Breast and prostate cancer are the most well-characterized cancers of the type that have
their development and growth controlled by the endocrine system. These cancers are the …

Abstract Learning Objectives After completing this course, the reader will be able to:
Understand the current treatment options available for postmenopausal women with breast …

Oestrogens (E) and oestrogen receptor alpha (ERα) play fundamental roles in the
development and progression of more than three-quarters of breast cancers (BC). The ability …

Breast cancer is the second leading cause of cancer deaths. This disease is estimated to be
diagnosed in over one million people worldwide and to cause more than 400,000 deaths …